Merck’s patent application entitled Method for Inhibiting Bone Resorption covers an increased unit dose of alendronate and other bisphosphonates for the treatment of Paget’s disease and osteoporosis.
The product covered by the patent is marketed as Fosomax® and has annual worldwide sales of over $1 billion.
The Patent Cooperation Treaty (PCT) application entered the national stage in Israel, and on allowance, the application was published for opposition purposes. Israel’s leading generic companies, Teva and Unipharm, opposed the application, alleging lack of novelty, lack of inventive step, lack of utility and non-patentable subject matter.
Following 12 days of hearings, Israel Commissioner of Patents, Dr. Noam, concluded:
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.